NextPoint Therapeutics
@NextPointTX
Followers
33
Following
1
Media
42
Statuses
45
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway.
Cambridge, MA
Joined November 2022
Data from NextPoint Therapeutics at #AACR-NCI-EORTC! NPX125, a B7-H7–targeting ADC, shows potent anti-tumor activity across solid tumor models. Reinforcing the promise of B7-H7 as a next-generation ADC target.
0
0
0
Headed to AACR-NCI-EORTC! Sr. Scientist Emilien Loeuillard will present a poster on NPX125, our novel ADC targeting B7-H7, a molecule central to tumor immune escape and highly expressed in tumors.
0
0
0
Join NextPoint Chief Scientific Officer Tatiana Novobrantseva and Director, Research and Development Melissa Hayes, at #SITC25 where they will be presenting the poster: TMIGD2 co-stimulation in a trispecific T cell engager elicits potent anti-tumor activity.
0
0
0
Heading to the ADC Linker & Conjugation Summit? Catch NextPoint CSO Tatiana Novobrantseva, PhD, on Aug 20 as she shares unique attributes of NPX125, a DAR8 B7-H7 targeting ADC with a novel linker. Can't make it? Let's connect!
0
0
0
NextPoint CSO Tatiana Novobrantseva, PhD, will moderate a plenary panel at the #IOSummit on Aug 13: "Accelerating IO through Target Discovery." Proud to see B7-H7 biology and smart target selection front and center in solid tumor IO.
0
0
0
NextPoint VP of Innovation Bijan Etemad-Gilbertson is heading to #BIO2025. We're advancing first-in-class precision therapeutic targeting the B7-H7 axis. Let’s connect in Boston to talk ADCs, TCEs & more.
0
0
0
CSO Tatiana Novobrantseva is featured in Databird’s “30 Visioneers Shaping the Future of Biotech in 2025.” She shares how NextPoint’s B7-H7 pathway approach offers a new angle on immune activation beyond PD-L1. Read more: https://t.co/36fWmHvbpX
0
1
3
CMO Dr. Leena Gandhi, MD, PhD, speaks at Stanford's Stat4Onc Symposium on “Maintaining Flexibility in Dose Optimization in Early Phase Oncology Trials.” Don’t miss this expert-packed session on dose optimization across the drug lifecycle! #Stat4Onc #OncologyTrials
0
0
0
#AACR2025 Recap: B7-H7-ADC NPX125 ✅ Tumor-selective ✅Minimal normal tissue ✅High receptor density Strong interest in NPX125’s targeting & proprietary linker tech.
1
0
0
NextPoint to present pioneering preclinical data on NPX125, our B7-H7-targeted ADC, at #AACR2025. With proprietary linker tech + validated payload, NPX125 shows potent cytotoxicity + strong tumor activity. Learn more: https://t.co/lr2lZNdo3t
0
1
1
NextPoint Co-Founder Dr. Gordon Freeman, pioneer of PD-L1/PD-L2, will speak at the Festival of Biologics on antibody-based checkpoint inhibition. A true leader in cancer immunotherapy. #FestivalOfBiologics #Immunotherapy
0
0
0
NextPoint is presenting 4 posters at #AACR2025! We're showcasing preclinical data on our B7-H7-targeted ADC and TCE programs. B7-H7 is upregulated across multiple cancer types with limited normal tissue expression— an ideal precision oncology target. https://t.co/45EaxnsCDl
0
0
1
NextPoint Co-founder Dr. Gordon Freeman & CSO Dr. Tatiana Novobrantseva will be speaking at IO360. Check them out during the New Tech in Transformational Biology track. #IO360Summit
0
0
0
Our CSO, Dr. Tatiana Novobrantseva, speaks with IO360 on developing B7-H7 therapies—potentially launching the "second wave of IO" for cancer patients unresponsive to current checkpoint inhibitors. Target both T & NK cells. Full interview: https://t.co/wGxc1Qfxtj
0
0
1
Meet us at Leerink Partners' Global Healthcare conference, March 10-12. CEO Ivan Cheung and CBO Paul Conrad will be discussing NextPoint’s B7-H7 targeted therapies that offer a unique approach beyond traditional PD-L1 pathways for TCEs & ADCs. https://t.co/g2vxqaac19
0
0
0
Our CSO @Tatiana Novobrantseva featured in Scrip's "What Does 2025 Hold for BioPharma?" sharing insights on solid tumor immunotherapy advances, including promising B7-H7 checkpoint pathway research. Full article: https://t.co/5muQeeT9cv
0
1
3
NextPoint's 2025 kicks off at #JPM2025! Our Executive team is heading to San Francisco to discuss our multimodal oncology pipeline targeting B7-H7-positive patients. A novel checkpoint pathway independent of PD-L1 that could transform cancer treatment. https://t.co/m2ElFtxzeO
0
0
0
NextPoint Therapeutics CEO Ivan Cheung will be speaking at the Piper Sandler Healthcare Conference about the company’s multimodal oncology pipeline that targets B7-H7-positive patients. https://t.co/FyWruSjbYS Reach out to learn more! https://t.co/g2vxqa9EbB
0
0
1
NextPoint Therapeutics CEO Ivan Cheung will be speaking at the upcoming Stifel Healthcare Conference on Tuesday, Nov 19 at 9:45 am. Learn about NextPoint’s pioneering B7-H7 targeted therapies that offer a unique approach beyond traditional PD-L1 pathways https://t.co/hGRQVHt6ca
0
0
0
Exciting Preclinical Data on Our Novel B7-H7 T Cell Engager Announced at #SITC2024! This innovative approach shows promise in overcoming the tumor microenvironment challenges. Can't join us in Houston? Explore the details here: https://t.co/KGQYxIE27D
0
1
1